Novartis

Novartis’ AveXis doubles down with $115M manufacturing investment
Novartis’ AveXis doubles down with $115M manufacturing investment
Fierce Pharma
Novartis
AveXix
North Carolina
hirings
drug manufacturing
Flag link:
Novartis Positioned to Be World's Top Drug Seller in 2024
Novartis Positioned to Be World's Top Drug Seller in 2024
Yahoo/Guru Focus
Novartis
Flag link:
NICE provides first scientific advice on patient preference
NICE provides first scientific advice on patient preference
BioCentury
NICE
COPD
Novartis
clinical trials`
Flag link:
Medicare would cover CAR-T cell therapies under new CMS proposal
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Medicare
CAR-T
cell therapy
CMS
Novartis
Kymriah
Gilead Sciences
Yescarta
Flag link:
Novartis secures regulatory 'fast pass' in US OK for tropical disease drug
Novartis secures regulatory 'fast pass' in US OK for tropical disease drug
Biopharma Dive
Novartis
FDA
Egaten
fast pass
priority review
Flag link:
Novartis inks 10-target antibody discovery deal with AbCellera
Novartis inks 10-target antibody discovery deal with AbCellera
Fierce Biotech
Novartis
R&D
antibodies
AbCellera
Flag link:
Pharma Novartis chief’s 2018 take-home pay suffers—not from Cohen but from low-grade returns
Pharma Novartis chief’s 2018 take-home pay suffers—not from Cohen but from low-grade returns
Fierce Pharma
Pharma CEOs
Novartis
executive pay
Vas Narasimhan
Flag link:
Clinigen Group Acquires U.S. Rights to Proleukin from Novartis
Clinigen Group Acquires U.S. Rights to Proleukin from Novartis
BioSpace
Novartis
Clinigen
Proleukin
metastatic renal cell carcinoma
Flag link:
Novartis CEO lauds Trump administration plan to overhaul rebates
Novartis CEO lauds Trump administration plan to overhaul rebates
Yahoo/Reuters
Novartis
Vas Narasimhan
Pharma CEOs
drug pricing
Donald Trump
drug rebates
Flag link:
Novartis spend on digital and data ‘in the 100s of millions’
Novartis spend on digital and data ‘in the 100s of millions’
Pharma Times
Novartis
digital health
clinical trial data
Flag link:
Mark Your Calendar For These February PDUFA Dates
Mark Your Calendar For These February PDUFA Dates
Yahoo/Benzinga
FDA
DWP-450
Evolus
MOTIF BIO PLC/S ADR
Iclaprim
Bausch Health
Duobrii
Merck
Keytruda
Incyte
Novartis
ruxolitinib
Novo Nordisk
N8-GP
Flag link:
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Pharmaforum
CAR-T
CAR-T Congress
oncology
Novartis
Kymriah
Europe
Flag link:
‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts
‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts
Fierce Pharma
Novartis
Sandoz
layoffs
drug manufacturing
Flag link:
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Fierce Pharma
Novartis
Kymriah
CAR-T
UK
diffuse large B-cell lymphoma
Gilead Sciences
Flag link:
Novartis plots new course for Sandoz
Novartis plots new course for Sandoz
BioCentury
Novartis
Sandoz
generics
Flag link:
As Novartis Eyes Growth in 2019, the Company Will Likely Cut Some Prices
As Novartis Eyes Growth in 2019, the Company Will Likely Cut Some Prices
BioSpace
Novartis
drug pricing
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Fierce Pharma
Novartis
ICER
spinal muscular atrophy
alternative payments
drug pricing
gene therapy
Zolgensma
Flag link:
Pfizer, Novartis, Amgen add to 2019 drug price hikes
Pfizer, Novartis, Amgen add to 2019 drug price hikes
Biopharma Dive
drug pricing
Pfizer
Novartis
Amgen
Flag link:
Novartis urges Britain to secure drug supplies before Brexit
Novartis urges Britain to secure drug supplies before Brexit
Yahoo/Reuters
Novartis
UK
Brexit
Europe
drug shortages
Flag link:
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
Motley Fool
FDA
gene editing
Novartis
Sarepta Therapeutics
CAR-T
Alzheimer's disease
Flag link:

Pages